Thomas Hope, MD
Imaging agents for the detection of biochemical recurrent prostate cancer could move beyond computed tomography (CT) and magnetic resonance imaging (MRI) in the near future, with the emergence of prostate-specific membrane antigen (PSMA)-PET, particularly in oligometastatic disease, with a high-detection sensitivity rate, explains Thomas Hope, MD.
on Genitourinary Cancers. In an interview during the meeting, Hope spread the word about this novel technique and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.
OncLive: Please provide an overview of your presentation on the modern era of imaging in prostate cancer.
I spoke about novel imaging techniques and how they impact the staging and treatment of patients with prostate cancer. I tried to highlight a couple of things; first, that there are some new FDA-approved agents, particularly fluciclovine (Axumin), which are available and are approved in patients with biochemical recurrent prostate cancer.
... to read the full story